Relevant bibliographies by topics / NIVACOR Trial

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'NIVACOR Trial'

Author: Grafiati
Published: 14 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'NIVACOR Trial.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "NIVACOR Trial"

1

Damato, Angela, Francesco Iachetta, Nicola Normanno, et al. "NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients." Journal of Clinical Oncology 38, no. 15_suppl (2020): TPS4118. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps4118.

Full text
Abstract:
TPS4118 Background: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has been shown to be one of the therapeutic regimens in first line with the highest activity profile in patients (pts) with metastatic colorectal cancer (mCRC) unselected for biomolecular alterations. Tumors co-opt the PD-1/PD-L1 signaling pathway as one key mechanism to evade immune destruction. Anti-PD-1 monoclonal antibodies are FDA approved only for DNA mismatch repair deficient/microsatellite instability-high (MMRd/MSI-H), which are only about 5% among all mCRC. Nowadays, there are no da
APA, Harvard, Vancouver, ISO, and other styles
2

Damato, Angela, Annalisa Berselli, Francesco Iachetta, et al. "Preliminary safety analysis of phase II open-label NIVACOR trial (GOIRC-03-2018) in patients with advanced colorectal cancer RAS or BRAF mutated." Journal of Clinical Oncology 39, no. 3_suppl (2021): 37. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.37.

Full text
Abstract:
37 Background: NIVACOR trial is an open-label, multicentric Italian phase II trial of FOLFOXIRI/bevacizumab in association with an anti-PD1 antibody, nivolumab, in patients (pts) with metastatic colorectal cancer (mCRC). We report preliminary safety analysis by an Independent Monitoring Committee. Methods: Pts with mCRC RAS or BRAF mutated, regardless microsatellite status and eligible to receive a first line treatment will be enrolled. FOLFOXIRI/bevacizumab (BEV) in association with nivolumab (NIV) was administered every 2 weeks for 8 cycles (induction) followed by BEV plus NIV every 2 weeks
APA, Harvard, Vancouver, ISO, and other styles
3

Damato, A., F. Bergamo, L. Antonuzzo, et al. "422P Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)." Annals of Oncology 33 (September 2022): S728. http://dx.doi.org/10.1016/j.annonc.2022.07.560.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Serafini, Mara Serena, Stefano Cavalieri, Lisa Licitra, et al. "Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab." Journal for ImmunoTherapy of Cancer 12, no. 1 (2024): e007823. http://dx.doi.org/10.1136/jitc-2023-007823.

Full text
Abstract:
BackgroundImmune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and comparing the predictive role of gene-expression signatures with classical biomarkers for immunotherapy-treated R/M HNSCC patients in a multicentric phase IIIb trial.MethodsClinical data were prospectively collected in Nivactor tiral (single-arm, open-label, multicenter, phase IIIb clinical trial in plat
APA, Harvard, Vancouver, ISO, and other styles
5

Taranto, Eleanor, Nicholas J. Seewald, Lauren J. Bayne, et al. "Abstract PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study." Clinical Cancer Research 31, no. 12_Supplement (2025): PS9–03—PS9–03. https://doi.org/10.1158/1557-3265.sabcs24-ps9-03.

Full text
Abstract:
Abstract Background: Recurrence after early-stage breast cancer (BC) is a challenge, occurring in ∼30% of patients (pts). Recurrences may arise from reactivation of disseminated tumor cells (DTCs) persisting in a dormant state after primary treatment. The presence of minimal residual disease (MRD) as bone marrow DTCs and/or circulating tumor DNA (ctDNA) in the blood increases the risk of BC recurrence/death. It remains unclear which pts with DTCs will have these reactivate or develop detectable ctDNA before clinical relapse. We evaluated the association and temporal relationship of ctDNA with
APA, Harvard, Vancouver, ISO, and other styles
6

Kaufmann, Tara, Patrick Chang, Shoshana Rosenberg, et al. "Abstract P5-08-01: Pilot study of a patient-reported outcome (PRO) measurement strategy to determine impact of screening for minimal residual disease (MRD) in high-risk breast cancer survivors." Cancer Research 83, no. 5_Supplement (2023): P5–08–01—P5–08–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-08-01.

Full text
Abstract:
Abstract Background: Patients treated for early stage breast cancer (BC) have a 30% lifetime risk of developing metastatic disease. Numerous studies have demonstrated that dormant bone marrow disseminated tumor cells (DTCs) are independently associated with risk of recurrence and death, yet interventions targeting these cells are lacking. The PENN-SURMOUNT (Surveillance Markers of Utility for Recurrence after (Neo)adjuvant Therapy) Screening Study was launched in 2016 to screen high risk BC survivors for DTCs using bone marrow aspirate (BMA) and identify eligible DTC positive patients for clin
APA, Harvard, Vancouver, ISO, and other styles
7

Damato, Angela, Francesca Bergamo, Lorenzo Antonuzzo, et al. "FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial." Frontiers in Oncology 11 (December 14, 2021). http://dx.doi.org/10.3389/fonc.2021.766500.

Full text
Abstract:
The NIVACOR trial is a phase II study assessing the efficacy and safety of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line setting in patients affected by metastatic colorectal cancer (mCRC) RAS/BRAF mutated. We report safety run-in results in the first 10 patients enrolled. Patients received triplet chemotherapy with FOLFOXIRI scheme plus bevacizumab, in association with nivolumab every 2 weeks for 8 cycles (induction phase) followed by bevacizumab plus nivolumab every 2 weeks (maintenance phase), until progression of disease or unacceptable toxicities. The first ten patient
APA, Harvard, Vancouver, ISO, and other styles
8

Damato, Angela, Francesco Iachetta, Lorenzo Antonuzzo, et al. "Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)." BMC Cancer 20, no. 1 (2020). http://dx.doi.org/10.1186/s12885-020-07268-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "NIVACOR Trial"

1

DAMATO, ANGELA. "Clinical and Biological Analysis in patients treated with NIVolumab plus FOLFOXIRI/Bevacizumab for Advanced COloRectal Cancer RAS or BRAF mutated: the phase II NIVACOR Trial." Doctoral thesis, Università di Siena, 2022. http://hdl.handle.net/11365/1194567.

Full text
Abstract:
The phase II NIVACOR trial, an open-label, multicenter study, was designed to assess in the first-line setting, the efficacy and safety in patients affected by mCRC RAS/BRAF mutated, an anti-PD-1 antibody, nivolumab, in combination with chemotherapy triplet scheme (FOLFOXIRI) plus an anti-VEGF antibody, bevacizumab. The preliminary safety run-in analysis performed by an Independent Monitoring Committee (IDMC), after the 10th patient enrolled was conducted. The main grade 1-2 adverse events (AEs) related to FOLFOXIRI/bevacizumab affect mainly diarrhea and fatigue (71%), nausea and vomiting (57%
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography